Vernalis

Vernalis is a UK-based specialty pharmaceutical company with two marketed products, Apokyn® to treat immobilising "off" episodes in patients with advanced Parkinson's disease and Frova®, to treat migraine. The company has a broad development pipeline focused on neurology and central nervous system disorders.

Contact Details: Oakdene Court 613 Reading Road Winnersh Surrey RG41 5UA United Kingdom Tel: +44 (0)118 977 3133 Fax: +44 (0)118 989 9300 Email: WWW: www.vernalis.com/

Loading...

Recent Publications by Vernalis:
Drug discovery chemistry: a primer for the non-specialist. Like all scientific disciplines, drug discovery chemistry is rife with...	21st October, 2009	Medicinal Chemistry, Vernalis (R&D) Ltd., Granta Park, Cambridge CB21 6GB,	Drug Discov Today. 2009 Aug;14(15-16):731-44. Epub 2009 May 4. DOI Direct Link
Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. Inhibitors of the Hsp90 molecular chaperone are showing considerable...	22nd September, 2009	Vernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, UK.	J Med Chem. 2009 Aug 13;52(15):4794-809. DOI Direct Link
Discovery and optimization of potent and selective functional antagonists of the human adenosine A2B receptor. We herein report the discovery of a novel class of antagonists of the...	8th September, 2009	Vernalis (R&D) Ltd, Granta Park, Cambridge, CB21 6GB, UK.	Bioorg Med Chem Lett. 2009 Oct 15;19(20):5945-9. Epub 2009 Aug 14. DOI Direct Link
Antagonists of the human A(2A) receptor. Part 6: Further optimization of pyrimidine-4-carboxamides. Antagonists of the human A(2A) receptor have been reported to have...	22nd August, 2009	Department of Chemistry, Vernalis (R&D) Ltd, 613 Reading Road, Winnersh,	Bioorg Med Chem. 2009 Sep 15;17(18):6590-605. Epub 2009 Aug 5. DOI Direct Link
Antagonists of the human A(2A) receptor. Part 5: Highly bio-available pyrimidine-4-carboxamides. A novel series of antagonists of the human A(2A) receptor have been...	30th June, 2009	Vernalis (R+D) Ltd., Winnersh Wokingham, UK.	Bioorg Med Chem Lett. 2009 May 15;19(10):2664-7. Epub 2009 Apr 1. DOI Direct Link
→View more Vernalis research publications.

Press Releases on Vernalis:
Paul Capital Partners Promotes Ken Macleod To Partner	24th July, 2008	Paul Capital Partners	NEW YORK, July 24 /PRNewswire/ -- Paul Capital Partners today announced that Ken Macleod, Ph.D., has been promoted to Partner. Based in Paul Capital's London office, Dr. Macleod is
WWMR, Inc. Announces Launch of New Pain Clinic Monitor	4th June, 2008	WWMR, Inc.	SAN FRANCISCO, June 4 /PRNewswire/ -- Launch of the Pain Clinic Monitor, a new audit of Pain Clinics, was announced today by WWMR, Inc. a leader in pain reporting and analysis. First quarter 2008
Oxford Immunotec Appoints Dr Pamela Kirby as Chairman	1st December, 2004	Oxford Immunotec	Oxford Immunotec Appoints Dr Pamela Kirby as Chairman Oxford, UK; 7 December 2004 -- Oxford Immunotec, the T cell diagnostics company, today announced that it has appointed Dr Pamela Kirby
Vernalis regains control of North American rights to frovatriptan from	1st December, 2004	Vernalis	Vernalis regains control of North American rights to frovatriptan from Elan 30th March 2004. Highlights   ·         Vernalis reacquires the
Northbank Communications Strengthens PR Team with the Appointment of Dr	1st May, 2004	Northbank	Northbank Communications Strengthens PR Team with the Appointment of Dr Douglas Pretsell as Account Manager London, Manchester, Munich, 13th May 2004 … Northbank

BioNews Results for Vernalis:
Vernalis plc: Interim Management Statement for the period to 12 November 2009	Pharma Live:  Nov 13 2009 3:52AM Matching: vernalis
Vernalis plc: Interim Management Statement for the period to 12 November 2009	Therapeutics Daily:  Nov 12 2009 2:22PM Matching: vernalis
Biotech group Vernalis replaces departing GC with internal promotion	The Lawyer:  Nov 12 2009 8:03PM Matching: vernalis
TechMARK movers: Standard increases Kewill stake	Find:  Oct 26 2009 4:54PM Matching: vernalis
Vernalis Initiates Pilot Study of V3381 in Patients with Chronic Cough	Pharma Live:  Oct 6 2009 3:00PM Matching: vernalis
Promote your company here: BioNewsCast - Press Release Distribution	→View more Vernalis news.

Vernalis Clinical Trials:
Safety and Efficacy of Low Doses of V24343 in Obese Subjects

Vernalis Patents:
US Patent No.	Title
6197788	(-)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
6610685	Fused indole derivatives
6664397	Use of (+)mefloquine for the treatment of malaria
6706750	Indole derivatives process for their preparation, pharmaceutical compositions containing them and their medicinal application
6716878	Antimicrobial agents
→View more Vernalis patents.

Vernalis (VNLS) Financial information Links from Barchart
VNLS Quote from from Barchart.com
VNLS Chart from from Barchart.com
VNLS Profile from from Barchart.com
VNLS Opinion from from Barchart.com
→View more Vernalis finance information.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 13 individuals from Vernalis using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 374 times since April 2007, the link to the organisation's website has been followed 63 times

Recent Search Terms used to find this page: vernalis 2009 19 may | Vernalis Rd Ltd | vernalis hsp70 | .

Search for more companies in Winnersh

Search for more companies in Surrey

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Vernalis